Methods of treatment with compounds having RAR.sub..alpha. receptor specific or selective activity
US5965606A · kind A · utility
67Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 29, 1995 |
| Grant date | Oct 12, 1999 |
| Priority date | — |
| Expiry date | Dec 29, 2015 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N25/4866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Retinoid compounds which act specifically or selectively on RAR.sub..alpha. receptor subtypes in preference over RAR.sub..beta. and RAR.sub..gamma. receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.